ProQR Therapeutics N.V. Stock
ProQR Therapeutics N.V. Stock
A very strong showing by ProQR Therapeutics N.V. today, with an increase of €0.13 (6.810%) compared to yesterday's price.
ProQR Therapeutics N.V. is currently one of the favorites of our community with 10 Buy predictions and no Sell predictions.
With a target price of 5 € there is potential for a 154.97% increase which would mean more than doubling the current price of 1.96 € for ProQR Therapeutics N.V..
Our community identified positive and negative aspects for ProQR Therapeutics N.V. stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the ProQR Therapeutics N.V. stock. On the other hand our users think that "Company culture" could be a problem in the future.
Pros and Cons of ProQR Therapeutics N.V. in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ProQR Therapeutics N.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ProQR Therapeutics N.V. | 6.810% | 13.091% | 9.370% | -36.864% | -24.110% | 41.896% | -43.971% |
| Pharming Group | 1.150% | 6.104% | 2.187% | 74.854% | 61.797% | 34.563% | 27.887% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
Comments
ProQR Therapeutics (NASDAQ:PRQR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics N.V. (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics N.V. (NASDAQ: PRQR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $8.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat